CD274 and nasopharyngeal carcinoma: To clarify whether the efficacy of PD-1 inhibitors treatment for RM-NPC is related to the PD-L1 expression status of the tumor, we compared the ORR of PD-1 inhibitors in patients with PD-L1-positive and PD-L1-negative expressing NPC and showed that PD-1 inhibitors can benefit regardless of PD-L1 expression status, and the benefit was more pronounced in those with positive PD-L1 expression (ORR, 31% vs. 21%).